助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   脂治疗后 的翻译结果: 查询用时:0.027秒
图标索引 在分类学科中查询
所有学科
更多类别查询

图标索引 历史查询
 

脂治疗后
相关语句
  lipid-lowering treatment
     It suggests that the resistance of insulin improves lipid-lowering treatment in type 2 dia betic patients.
     提示 :2型糖尿病病人通过有效的调脂治疗后 ,胰岛素抵抗有所改善。
短句来源
  “脂治疗后”译为未确定词的双语例句
     3.After the administration of Spironalactone blood pressure in salt-sensitive hypertensive rats fell from (166.4±3.8)mm Hg to(116.4±8.3)mm Hg while [Ca~ 2+ ]_i fell from (175.8±23.6) nmol/L to(73.5±9.8)nmol/L,(P<0.01).
     (3)经螺内脂治疗后,该模型鼠尾收缩压降低,由(166.4±3.8)mmHg降至(116.4±8.3)mmHg,细胞内钙亦由(175.8±23.6)nmol/L降至(73.5±9.8)nmol/L,P<0.01,生化指标有改善。
短句来源
     The serum P selectin and OX LDL were reduced (1 26±0 38)mg·L -1 ,(0 92±0 33)mg·L -1 and serum NO was elevated [(113 26±27 75)mmol·L -1 , P <0 01]by the intervention of lipid regulation in the group of patients.
     调脂治疗后病例组血清P 选择素、OX LDL水平明显降低 (1 2 6± 0 3 8)mg·L-1、(0 92± 0 3 3 )mg·L-1,P <0 0 1,NO水平明显回升 (113 2 6± 2 7 75 )mmol·L-1,P<0 0 1。
短句来源
     The serum P-selection and OX-LDL reduced (1.250.37 mgL~(-1), 0.190.36 mgL~(-1)) and serum NO elevated (112.2527.76 mmolL~(-1),P<0.01) by the intervention of lipid lowing in the group of patients.
     调脂治疗后病例组血清P-选择素、OX-LDL水平明显降低(1.25±0.37mg.L1,0.91±0.36mg.L1,P<0.01),NO水平明显回升(112.25±27.76mmo1.L1,P<0.01)。
短句来源
     Results In simvastatin group, patients had a 15 4% reduction in serum cholesterol, 25 3% reduction in low density lipoprotein cholesterol, and 11 5% increase in high density lipoprotein cholesterol.
     结果 辛伐他汀组患者在接受降脂治疗后血清总胆固醇降低 15 4% ,低密度脂蛋白 胆固醇下降 2 5 3% ,高密度脂蛋白 胆固醇增加 11 5 %。
短句来源
     Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
     目的 :探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素 1的影响。
短句来源
更多       
  相似匹配句对
     The Treatment of Poststroke Depression
     卒中抑郁的治疗
短句来源
     Imaging Of Brain Tumors after Therapy
     治疗脑瘤的影像学
短句来源
     They had a good response to treatment of prednisone, riboflavin and low fat diet.
     经激素、核黄素及低饮食治疗好转。
短句来源
     Surgical management of lipoblastoma
     母细胞瘤的手术治疗
短句来源
     Superficial View the Treatment of Declining Fat of Fatty Liver Disease
     浅谈肪肝的降治疗
短句来源
查询“脂治疗后”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  lipid-lowering treatment
The US trial, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial (ALLHAT-LLT), was reported as showing no significant benefit.
      
By failing to recognize the heterogeneity of hypertension, the authors of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study used a faulty premise to conduct a poorly designed clinical trial.
      
The publication of the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) results, when used in conjunction with a new meta-analysis, provides hypertension research with a watershed.
      
Combined antihypertensive and lipid-lowering treatment
      
In this article, we discuss and critically evaluate the available evidence on the potential benefits of combined antihypertensive and lipid-lowering treatment.
      
更多          


Objective:In order to clarify the effects of lipid lowering therapy on plasma endothelin and insulin resistance in patients with coronary heart disease(CHD). Methods:Fasting serum lipids,glucose and insulin and plasma endothelin were measured and insulin sensitivity index(ISI) was calculated in 30 healthy subjects and 70 non diabetic patients with CHD before and after 4 weeks of simvastatin treament (5mg/d).Serum glucose and insulin were measured during oral glucose tolerance test (OGTT) in patient group....

Objective:In order to clarify the effects of lipid lowering therapy on plasma endothelin and insulin resistance in patients with coronary heart disease(CHD). Methods:Fasting serum lipids,glucose and insulin and plasma endothelin were measured and insulin sensitivity index(ISI) was calculated in 30 healthy subjects and 70 non diabetic patients with CHD before and after 4 weeks of simvastatin treament (5mg/d).Serum glucose and insulin were measured during oral glucose tolerance test (OGTT) in patient group. The areas under the glucose tolerance curve and insulin releasing curve were also calculated. Results:①After simvastatin treament,serum TC,TG,LDL C and Apo B were lower and HDL C,Apo AⅠ were higher than those before.②Plasma endothelin in patients with CHD was obviously higher than in normal subjects.After treament,endothelin in patients with CHD decreased by 30%.③ISI in patients with CHD was obviously lower than in normal subjects( p <0 01).After simvastatin administration,insulin,insulin/glucose(I/G) ratio and the areas under the curve for insulin and I/G( I, I/G )during OGTT were significantly reduced ( p <0 05).ISI was remarkably increased after treament.④In patient group,serum TC was positively correlated with plasma endothelin(ET) and insulin level at 60min,120min after loading and the area under the curve for insulin ( r =0 38,0 36,0 32,0 34,respectively,all p <0 05);ET was positively correlated with insulin level at 60min,120min after loading and the area under the curve for insulin( r =0 43,0 44,0 46,respectively,all p <0 01). Conclusion:The results suggest that lipid lowering therapy has beneficial effects on lowering plasma ET and improving insulin resistance(IR).The interaction between serum lipids and ET and IR might be involved in the development of CHD.

目的:探讨冠心病患者在降脂治疗的同时对血浆内皮素及胰岛素抵抗的影响。方法:测定70例冠心病患者(冠心病组,血清总胆固醇≥5.2mmol/L)降脂治疗(辛伐他汀,5mg/d,疗程4周)前后及30例健康人(正常对照组)血脂、血浆内皮素、空腹血糖、胰岛素及计算胰岛素敏感性变化。测定冠心病组降脂治疗前后、糖耐量试验前后血糖及胰岛素水平,并计算曲线下面积。分别分析血清总胆固醇与血糖、血浆内皮素、胰岛素及其曲线下面积的相关性;血浆内皮素与胰岛素及其曲线下面积的相关性。结果:①冠心病组用辛伐他汀降脂疗效肯定。②血浆内皮素在冠心病组显著高于正常对照组,冠心病组降脂治疗后比治疗前血浆内皮素下降30%。③冠心病组胰岛素敏感性指数显著低于正常对照组(P<0.01)。冠心病组空腹及糖负荷后血胰岛素水平,血胰岛素/葡萄糖及各曲线下面积在治疗后均有下降(P<0.05),胰岛素敏感性指数上升。④冠心病组血清总胆固醇分别与血浆内皮素,服糖后60分钟、120分钟胰岛素及胰岛素曲线下面积呈正相关(r分别为0.38,0.36,0.32,0.34,P均<0.05);血浆内皮素分别与服糖后60分钟、120分钟胰岛素及胰岛素曲线下面积呈显著...

目的:探讨冠心病患者在降脂治疗的同时对血浆内皮素及胰岛素抵抗的影响。方法:测定70例冠心病患者(冠心病组,血清总胆固醇≥5.2mmol/L)降脂治疗(辛伐他汀,5mg/d,疗程4周)前后及30例健康人(正常对照组)血脂、血浆内皮素、空腹血糖、胰岛素及计算胰岛素敏感性变化。测定冠心病组降脂治疗前后、糖耐量试验前后血糖及胰岛素水平,并计算曲线下面积。分别分析血清总胆固醇与血糖、血浆内皮素、胰岛素及其曲线下面积的相关性;血浆内皮素与胰岛素及其曲线下面积的相关性。结果:①冠心病组用辛伐他汀降脂疗效肯定。②血浆内皮素在冠心病组显著高于正常对照组,冠心病组降脂治疗后比治疗前血浆内皮素下降30%。③冠心病组胰岛素敏感性指数显著低于正常对照组(P<0.01)。冠心病组空腹及糖负荷后血胰岛素水平,血胰岛素/葡萄糖及各曲线下面积在治疗后均有下降(P<0.05),胰岛素敏感性指数上升。④冠心病组血清总胆固醇分别与血浆内皮素,服糖后60分钟、120分钟胰岛素及胰岛素曲线下面积呈正相关(r分别为0.38,0.36,0.32,0.34,P均<0.05);血浆内皮素分别与服糖后60分钟、120分钟胰岛素及胰岛素曲线下面积呈显著正相关(r?

Objective To investigate the influence of PGI 2 stabilizing effect of sera from coronary artery disease (CAD) patients with hypertriglyceridemia and low HDL before and after fenofibrate treatment. Methods Twenty CAD patients and 20 healthy individuals were enrolled. The inhibitory rate of PGI 2 on ADP induced platelet aggregation was used as an index of PGI 2 biological activity. All CAD patients were given fenofibrate 300 mg daily for one month. The relationship between PGI 2 stabilizing effect and blood...

Objective To investigate the influence of PGI 2 stabilizing effect of sera from coronary artery disease (CAD) patients with hypertriglyceridemia and low HDL before and after fenofibrate treatment. Methods Twenty CAD patients and 20 healthy individuals were enrolled. The inhibitory rate of PGI 2 on ADP induced platelet aggregation was used as an index of PGI 2 biological activity. All CAD patients were given fenofibrate 300 mg daily for one month. The relationship between PGI 2 stabilizing effect and blood lipids were compared before and after the treatment. Results Before treatment, the stabilizing effect of serum on PGI 2 activity decreased significantly in the CAD group as comparing with that of the control group ( P <0.01). One month after the treatment, HDL level in the CAD group increased significantly ( P <0.01), and TG level significantly decreased ( P <0.001). The difference of PGI 2 activity was no longer found between the CAD and control group ( P >0.05). Conclusion The results confirm the protective effect of HDL on PGI 2 biological activity. Low HDL is considered as an important risk factor of CAD therefore, impaired PGI 2 biological activity and increased platelet aggregation might be one of the mechanisms. Furthermore, raising HDL level by lipid modulating treatment could restore the protective effect of HDL on PGI 2 and might be beneficial in the prevention of acute coronary syndrome.

目的观察冠心病合并高甘油三酯(TG),低高密度脂蛋白-胆固醇(HDL-C)血症患者应用非诺贝特治疗后,其血清对前列环素(PGI2)生物活性的影响。方法选择冠心病组和正常组各20例,以PGI2对二磷酸腺苷(ADP)诱导的血小板聚集的抑制率作为PGI2生物活性的指标,在冠心病组服用非诺贝特前及一个月后,比较两组患者的血清对PGI2生物活性的影响及与血脂的关系。结果实验发现,在应用非诺贝特治疗前,冠心病组血清对PGI2生物活性的稳定作用明显低于正常组(P<0.01)。应用非诺贝特治疗1个月后,冠心病组的血TG水平显著降低(P<0.001),血HDL-C水平显著升高(P<0.01);同时,冠心病组血清对PGI2的稳定作用与正常组相比不再有显著性差异(P>0.05)。结论本实验进一步证实了HDL-C对PGI2的保护作用。因低HDL-C血症是冠心病的危险因子,因而其降低PGI2生物活性从而增加血小板聚集很可能是其作用机制的一部分。经过调脂治疗后,升高血HDL-C水平,恢复HDL-C对PGI2的保护作用对防止粥样斑块破裂和减少急性冠状动脉综合征的发生可能起重要作用。

The level of plasma oxidated low density lipoprotein (OX-LDL), apolipoprotein E(ApoE) were measured by single antibody enzyme linked immunosorbent assay in 40 non-insulin-dependent diabetes mellitus (NIDDM) patients and in 20 normal subjects. Changes of the plasma OX-LDL,ApoE were also observed in 20 NIDDM patients treated with fenofibrate. Results: The plasma OX-LDL, ApoE concentration were higher in NIDDM patients than those in controls (P < 0. 01, P < 0 .05). The level of plasma OX-LDL, ApoE in 22 NIDDM...

The level of plasma oxidated low density lipoprotein (OX-LDL), apolipoprotein E(ApoE) were measured by single antibody enzyme linked immunosorbent assay in 40 non-insulin-dependent diabetes mellitus (NIDDM) patients and in 20 normal subjects. Changes of the plasma OX-LDL,ApoE were also observed in 20 NIDDM patients treated with fenofibrate. Results: The plasma OX-LDL, ApoE concentration were higher in NIDDM patients than those in controls (P < 0. 01, P < 0 .05). The level of plasma OX-LDL, ApoE in 22 NIDDM patients with vascular disease increased significantly in comparison with those in 18 NIDDM patients without vascular disease (P < 0 .05). The level of plasma OX-LDL, ApoE also markedly reduced in 20 NIDDM patients after the treatment with fenofibrate (P< 0. 05). There was no significant correlation between the level of plasma OX-LDL and serum cholesterol, triglyceride, high density lipoprotein, ApoE. Conclusion: It was suggested that elevated OX-LDL might be a risk factor related to vascular disease in NIDDM patient. Fenofibrate might take effect in preventing NIDDM patient from the development of vascular disease.

采用单抗 ELISA法测定了 40例 Ⅱ型糖尿病患者及 20例正常对照组血浆 OX-LDL、Apo E水平。结果显示:(1)DM组较对照组OX-LDL、ApoE水平显著增高(P<0.05,P<0.05)。DM伴血管病变组与无血管病变组比较,前者血浆 OX-LDL、Apo E水平显著增高( P< 0.05)。(2)20例 Ⅱ型糖尿病患者经力平脂治疗后血浆 OX-LDL、Apo E水平显著下降。(3)血浆 OX-LDL与血 ch、TG、Apo E、HDL-ch均无显著相关性。提示 OX-LDL可能与糖尿病血管并发症有关,力平脂治疗对预防血管病变的发生有一定的作用。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关脂治疗后的内容
在知识搜索中查有关脂治疗后的内容
在数字搜索中查有关脂治疗后的内容
在概念知识元中查有关脂治疗后的内容
在学术趋势中查有关脂治疗后的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社